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Hypoglycemia occurs commonly in the diabetic patient. In 
some clinical situations, a hypoglycemic workup is 
indicated when concerned about an endogenous cause. Even 
so, iatrogenic causes of hypoglycemia in known diabetics 
must be ruled out to avoid unnecessary testing and therapy. 
In the setting of severe hypoglycemia, understanding the 
etiology is crucial as this could ultimately lead to death if 
untreated. 
HPI - A 69 year old African American male was admitted 
for persistent symptomatic hypoglycemia (dizziness, blurry 
vision, sweats, lethargy, and fatigue). He is a known 
diabetic of 6 years duration with good glycemic control. He 
was admitted to the hospital twice, within a 5 month time 
frame, with glucose levels in the 30’s. 
PMH/PSH – CAD, ICM, HTN, HLD, CKD, DM2, 
Pacemaker placement 
Social history – Single, Disabled, Former Smoker, No 
EtOH, No illicit drugs 
Family History – Mother: DM2, Father: Heart Failure 
Medications – Plavix, Triamcinolone cream, Losartan, 
Carvedilol, Spironolactone, Furosemide, Aggrenox, 
Allopurinol, Omega-3 Fatty Acids, ASA, Ranitidine, 
Lovastatin, Nitroglycerin 
Physical Exam – Hypotension, otherwise VSS, exam 
unremarkable other than 1+ pitting edema in bilateral lower 
extremities 
Labs – revealed low glucose, elevated creatinine, elevated 
BUN 
Medication Reconciliation – An extensive medication 
reconciliation ensued, evaluating administration of insulin 
secretagogues (patient previously was on glimepiride). He 
and his family were adamant that he was not taking any 
glucose lowering agents as previously instructed at his last 
hospitalization for the same problem. 
 
 
•Persistent hypoglycemia despite multiple Dextrose 50 injections 
•D10 drip started with and still with some persistent hypoglycemia. (Graph 
1) 
•A 72 hour fast was initiated, and the glucose trend while fasting is 
demonstrated in Graph 2. It was anticipated that the patient’s glucose level 
would quickly drop when withholding food and D10.  
• Initial glucose within normal range 
• Quickly equilibrated and blood glucose unexpectedly began to rise. 
• Pro-insulin, C-peptide, and insulin levels were drawn and all elevated 
at start of fast.  
•After the fast was initiated the patient’s family brought his medications 
from home for review. 
• Glimepiride 4 mg amongst his medication bottles. 
• Admitted to usage for 2 days prior to admission. 
• The fast was terminated and medication counseling for cessation 
ensued 
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Graph 2: Glucose during fast 
Hypoglycemia in the diabetic patient: 
Hypoglycemia in the diabetic patient is usually secondary to exogenous insulin and/or oral 
diabetic agents whether it be accidental, surreptitious, or malicious. 
In this patient the use of exogenous agents was adamantly denied by patient and family, he 
had received counseling on this multiple times before. Therefore, the concern in an otherwise 
well individual would broaden the differential to include:  
1)  Insulinoma 
2)  Nesidioblastosis 
3)  Insulin autoimmune hypoglycemia 
If Whipple’s triad is present, a 72-hour fast is the diagnostic test of choice in determining the 
etiology of hypoglycemia.  This involves monitoring of glucose levels and correlating levels 
of Insulin, Pro-insulin, C- Peptide, and Beta-hydroxybutyrate with hypoglycemic level. 
Sulfonylurea induced hypoglycemia: 
Hypoglycemia is a well known side effect of oral sulfonylureas. In a study comparing 
glyburide to glimepiride, prevalence of more severe hypoglycemia with glyburide was 
suggested to be due to renal clearance. Even so, hypoglycemia remains a major side effect of 
Glimepiride. 
Treatment: 
The first intervention is cessation of the offending agent (in this case Glimepiride). Next is 
supportive treatment of hypoglycemia with dextrose infusions and carbohydrate rich oral intake 
with close glucose monitoring until medication has cleared. There has also been some efficacy 
shown with utilization of Octreotide as an antidote for sulfonylureas. 
Prevention: 
Ultimately, prevention is the best intervention. Adequate counseling on proper use and, in this 
case, cessation should be offered, followed by close follow-up. 
 
 
 
 
 
 
PGBH, post gastric bypass hypoglycemia.   
a Free C-peptide and proinsulin concentrations are low 
b Increased pro-IGF-II, free IGF-II, IGF-II/IGF-I ratio 
(Table 3:Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, March 2009, 94(3):709-728.) 
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J= Juice 
M= Milk 
Meal = Full meal 
